Get the Stockscreener App
11.67
0.26%
-0.03
After Hours:
11.72
0.05
+0.43%
Range Cancer Therapeutics Etf stock is traded at $11.67, with a volume of 1,105.
It is down -0.26% in the last 24 hours and down -7.79% over the past month.
See More
Previous Close:
$11.70
Open:
$11.7577
24h Volume:
1,105
Relative Volume:
0.31
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.61%
1M Performance:
-7.79%
6M Performance:
-25.10%
1Y Performance:
-13.75%
1-Day Range:
$11.67
$11.76
1-Week Range:
$11.38
$11.98
52-Week Range:
$11.38
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Name
Range Cancer Therapeutics Etf
Sector
Industry
Phone
-
Address
-
Compare CNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
11.67 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
296.20 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
597.58 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
600.26 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
248.52 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
521.74 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Stock (CNCR) Latest News
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
(CNCR) Investment Analysis - Stock Traders Daily
7 Best-Performing Biotech ETFs for January 2025 - NerdWallet
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
Daniel Dunaief - TBR News Media
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
The Best Biotech Stocks to Buy - Morningstar
Charted: Cancer Survival Rates Over Time - Visual Capitalist
Range Cancer Therapeutics - TBR News Media
How this award-winning TV host is setting the stage to help protect her health - TBR News Media
Investment fund pledges revenues in cancer research partnership with CSHL - TBR News Media
(CNCR) Trading Signals - Stock Traders Daily
At a Glance: Nov. 6 - Crain's New York Business
The 5 Best Biotech ETFs of 2024 - TradingView
Seagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of Cancers - BNN Bloomberg
SPDR Galaxy Hedged Digital Asset Ecosystem ETF (HECO-Q) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Science & Technology - TBR News Media
(CNCR) Investment Report - Stock Traders Daily
How are ADC drug partnerships changing China’s biotech landscape? - Invesco
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
Trackinsight ETF data from 23rd to 27th September, 2024 - ETF Express
(CNCR) Investment Analysis and Advice - Stock Traders Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Roundhill Investments Surpasses $2 Billion AUM Milestone – Company Announcement - Financial Times
5 ETFs That Led the Rebound on Monday - Yahoo Finance
IPO Roundup: Bicara Therapeutics, Kairos Pharma and more (NYSEARCA:IPO) - Seeking Alpha
Trading (CNCR) With Integrated Risk Controls - Stock Traders Daily
Cellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS) - Seeking Alpha
Best-Performing ETF Areas of Past Week - MSN
Range Cancer Therapeutics Etf Stock (CNCR) Financials Data
There is no financial data for Range Cancer Therapeutics Etf (CNCR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):